NasdaqGS:INMD

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. More Details


Snowflake Analysis

Flawless balance sheet with solid track record.


Similar Companies

Share Price & News

How has InMode's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: INMD's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

6.7%

INMD

0.6%

US Medical Equipment

0.09%

US Market


1 Year Return

38.9%

INMD

14.8%

US Medical Equipment

12.6%

US Market

Return vs Industry: INMD exceeded the US Medical Equipment industry which returned 14.8% over the past year.

Return vs Market: INMD exceeded the US Market which returned 12.6% over the past year.


Shareholder returns

INMDIndustryMarket
7 Day6.7%0.6%0.09%
30 Day14.4%0.9%-1.6%
90 Day17.6%11.4%7.9%
1 Year38.9%38.9%15.8%14.8%15.2%12.6%
3 Yearn/a72.3%67.9%38.9%29.6%
5 Yearn/a148.2%129.3%87.6%66.5%

Price Volatility Vs. Market

How volatile is InMode's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is InMode undervalued compared to its fair value and its price relative to the market?

24.04x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: INMD ($36.22) is trading above our estimate of fair value ($28.57)

Significantly Below Fair Value: INMD is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: INMD is good value based on its PE Ratio (24x) compared to the US Medical Equipment industry average (50.5x).

PE vs Market: INMD is poor value based on its PE Ratio (24x) compared to the US market (18.2x).


Price to Earnings Growth Ratio

PEG Ratio: INMD is poor value based on its PEG Ratio (1.1x)


Price to Book Ratio

PB vs Industry: INMD is overvalued based on its PB Ratio (6.3x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is InMode forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

22.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: INMD's forecast earnings growth (22.5% per year) is above the savings rate (2.2%).

Earnings vs Market: INMD's earnings (22.5% per year) are forecast to grow slower than the US market (23.2% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: INMD's revenue (18.1% per year) is forecast to grow faster than the US market (9.7% per year).

High Growth Revenue: INMD's revenue (18.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: INMD's Return on Equity is forecast to be high in 3 years time (22%)


Next Steps

Past Performance

How has InMode performed over the past 5 years?

60.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: INMD has high quality earnings.

Growing Profit Margin: INMD's current net profit margins (31.7%) are higher than last year (27.4%).


Past Earnings Growth Analysis

Earnings Trend: INMD's earnings have grown significantly by 60.7% per year over the past 5 years.

Accelerating Growth: INMD's earnings growth over the past year (47.9%) is below its 5-year average (60.7% per year).

Earnings vs Industry: INMD earnings growth over the past year (47.9%) exceeded the Medical Equipment industry -0.2%.


Return on Equity

High ROE: INMD's Return on Equity (24.5%) is considered high.


Next Steps

Financial Health

How is InMode's financial position?


Financial Position Analysis

Short Term Liabilities: INMD's short term assets ($233.6M) exceed its short term liabilities ($27.8M).

Long Term Liabilities: INMD's short term assets ($233.6M) exceed its long term liabilities ($5.1M).


Debt to Equity History and Analysis

Debt Level: INMD is debt free.

Reducing Debt: INMD has not had any debt for past 5 years.

Debt Coverage: INMD has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: INMD has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is InMode current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate INMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate INMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if INMD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if INMD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of INMD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.2yrs

Average management tenure


CEO

Moshe Mizrahy (67 yo)

12.67yrs

Tenure

US$216,000

Compensation

Mr. Moshe Mizrahy is a Co-founder of Home Skinovations Ltd. and serves as its Chairman and Chief Executive Officer. Mr. Mizrahy is also a Co-founder of InsightLook Technologies Ltd., Nizanim Venture Capita ...


CEO Compensation Analysis

Compensation vs Market: Moshe's total compensation ($USD216.00K) is below average for companies of similar size in the US market ($USD4.58M).

Compensation vs Earnings: Insufficient data to compare Moshe's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Moshe Mizrahy
Chairman & CEO12.67yrsUS$216.00k14.28%
$ 184.2m
Yair Malca
Chief Financial Officer3.67yrsUS$502.00k0%
$ 0
Michael Kreindel
CTO & Director1.08yrsUS$218.00k14.57%
$ 187.9m
Shakil Lakhani
President of North America3.67yrsUS$1.87m0%
$ 0
Spero Theodorou
Chief Medical Officerno dataUS$1.23m0%
$ 0

8.2yrs

Average Tenure

48yo

Average Age

Experienced Management: INMD's management team is seasoned and experienced (8.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Moshe Mizrahy
Chairman & CEO12.67yrsUS$216.00k14.28%
$ 184.2m
Michael Kreindel
CTO & Director1.08yrsUS$218.00k14.57%
$ 187.9m
Michael Anghel
Independent Director1.08yrsno data0%
$ 0
Bruce Mann
Independent Director1.08yrsno data0.075%
$ 972.0k
Hadar Ron
Independent Director1.08yrsno data0.26%
$ 3.4m

1.1yrs

Average Tenure

67yo

Average Age

Experienced Board: INMD's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.7%.


Top Shareholders

Company Information

InMode Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: InMode Ltd.
  • Ticker: INMD
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$1.290b
  • Shares outstanding: 35.61m
  • Website: https://www.inmodemd.com

Number of Employees


Location

  • InMode Ltd.
  • Tavor Building
  • Sha’ar Yokneam
  • Yokneam
  • 2069206
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
INMDNasdaqGS (Nasdaq Global Select)YesOrdinary SharesUSUSDAug 2019

Biography

InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio freque ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/20 06:23
End of Day Share Price2020/09/18 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.